Skip to main content

Advertisement

SpringerLink
Log in

Off-Label Uses of Omalizumab

  • Published:
Clinical Reviews in Allergy & Immunology Aims and scope Submit manuscript

Abstract

The off-label use of medicines is a common and extensive clinical practice. Omalizumab has been licensed for use in severe allergic asthma and chronic urticaria. Omalizumab dosing was based on body weight and baseline serum IgE concentration. All patients are required to have a baseline IgE between 30 and 700 IU/ml and body weight not more than 150 kg. The use of off-label drugs may lead to several problems including adverse effects and an increased risk/benefit balance. In this article, there are summarized off-label uses of omalizumab in the last recent years in diseases in which IgE maybe or certainly has a corner role such as allergic rhinitis, allergic bronchopulmonary aspergillosis, anaphylaxis, keratoconjunctivitis, food allergy, drug allergy, urticaria, angioedema, non-atopic asthma, atopic dermatitis, nasal polyps, Churg-Strauss syndrome, eosinophilic otitis media, chronic rhinosinusitis, bullous pemphigoid, contact dermatitis, and others. Use in pregnancy asthmatic women and pre-co-administration with specific immunotherapy will also be revised.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Blondon K, Desmeules J, Vogt-Ferrier N, Besson M, Kondo-Oestreicher M, Dayer P (2008) Off-label prescribing. Rev Med Suisse 4(165):1661–5, La prescription “off-label”

    PubMed  Google Scholar 

  2. Radley DC, Finkelstein SN, Stafford RS (2006) Off-label prescribing among office-based physicians. Arch Intern Med 166(9):1021–6

    Article  PubMed  Google Scholar 

  3. Kesselheim AS, Mello MM, Avorn J (2013) FDA regulation of off-label drug promotion under attack. JAMA 309(5):445–6

    Article  PubMed  Google Scholar 

  4. Baird B, Shopes RJ, Oi VT, Erickson J, Kane P, Holowka D (1989) Interaction of IgE with its high-affinity receptor structural basis and requirements for effective cross-linking. Int Arch Allergy Appl Immunol 88(1–2):23–8

    Article  CAS  PubMed  Google Scholar 

  5. Makris MP, Papadavid E, Zuberbier T (2014) The use of biologicals in cutaneous allergies—present and future. Curr Opin Allergy Clin Immunol 14(5):409–16

    Article  CAS  PubMed  Google Scholar 

  6. Khan S, Deacock S (2011) Expanding indications of omalizumab therapy in the absence of specific IgE. Allerg Immunol (Madr) 39(3):189

    Article  CAS  Google Scholar 

  7. Holgate ST (2014) New strategies with anti-IgE in allergic diseases. World Allergy Organ J 7(1):17

    Article  PubMed Central  PubMed  Google Scholar 

  8. Babu KS, Polosa R, Morjaria JB (2013) Anti-IgE–emerging opportunities for omalizumab. Expert Opin Biol Ther 13(5):765–77

    Article  CAS  PubMed  Google Scholar 

  9. Danes I, Agusti A, Vallano A, Alerany C, Martinez J, Bosch JA et al (2014) Outcomes of off-label drug uses in hospitals: a multicentric prospective study. Eur J Clin Pharmacol 70(11):1385–93

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Hirashima J, Hojo M, Iikura M, Hiraishi Y, Nakamichi S, Sugiyama H et al (2012) A case of an asthma patient receiving omalizumab during pregnancy. Arerugi 61(11):1683–7

    PubMed  Google Scholar 

  11. Kuprys-Lipinska I, Tworek D, Kuna P (2014) Omalizumab in pregnant women treated due to severe asthma: two case reports of good outcomes of pregnancies. Postepy dermatologii i alergologii 31(2):104–7

    PubMed Central  PubMed  Google Scholar 

  12. Namazy J, Cabana MD, Scheuerle AE, Thorp JM, Jr., Chen H, Carrigan G, et al. (2014) The Xolair Pregnancy Registry (EXPECT): The safety of omalizumab use during pregnancy. J Allergy Clin Immunol

  13. Johansson SG, Oman H, Nopp A, Pettersson S (2006) The importance of IgE antibody levels in anti-IgE treatment. Allergy 61(10):1216–9

    Article  CAS  PubMed  Google Scholar 

  14. Ankerst J, Nopp A, Johansson SG, Adedoyin J, Oman H (2010) Xolair is effective in allergics with a low serum IgE level. Int Arch Allergy Immunol 152(1):71–4

    Article  CAS  PubMed  Google Scholar 

  15. Maselli DJ, Singh H, Diaz J, Peters JI (2013) Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL: a retrospective study. Ann Allergy Asthma Immunol 110(6):457–61

    Article  CAS  PubMed  Google Scholar 

  16. Vennera Mdel C, Picado C (2014) Novel diagnostic approaches and biological therapeutics for intrinsic asthma. Int J General Med 7:365–71

    Article  CAS  Google Scholar 

  17. de Llano LP, Vennera Mdel C, Alvarez FJ, Medina JF, Borderias L, Pellicer C et al (2013) Effects of omalizumab in non-atopic asthma: results from a Spanish multicenter registry. J Asthma 50(3):296–301

    Article  PubMed  CAS  Google Scholar 

  18. Garcia G, Magnan A, Chiron R, Contin-Bordes C, Berger P, Taille C et al (2013) A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma. Chest 144(2):411–9

    Article  CAS  PubMed  Google Scholar 

  19. Domingo C, Pomares X, Angril N, Rudi N, Amengual MJ, Mirapeix RM (2013) Effectiveness of omalizumab in non-allergic severe asthma. J Biol Regul Homeost Agents 27(1):45–53

    CAS  PubMed  Google Scholar 

  20. Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P, Judson MA et al (2003) Allergic bronchopulmonary Aspergillosis in cystic fibrosis–state of the art: cystic fibrosis foundation consensus conference. Clin Infect Dis 37(Suppl 3):S225–64

    Article  PubMed  Google Scholar 

  21. Knutsen AP, Slavin RG. (2011) Allergic Bronchopulmonary Aspergillosis in Asthma and Cystic Fibrosis. Clinical and Developmental Immunology

  22. Greenberger PA, Patterson R (1988) Allergic bronchopulmonary aspergillosis and the evaluation of the patient with asthma. J Allergy Clin Immunol 81(4):646–50

    Article  CAS  PubMed  Google Scholar 

  23. Laufer P, Fink JN, Bruns WT, Unger GF, Kalbfleisch JH, Greenberger PA et al (1984) Allergic bronchopulmonary aspergillosis in cystic fibrosis. J Allergy Clin Immunol 73(1 Pt 1):44–8

    Article  CAS  PubMed  Google Scholar 

  24. Zicari AM, Celani C, De Castro G, Valerio De Biase R, Duse M (2014) Anti IgE antibody as treatment of allergic bronchopulmonary aspergillosis in a patient with cystic fibrosis. Eur Rev Med Pharmacol Sci 18(13):1839–41

    CAS  PubMed  Google Scholar 

  25. Tanou K, Zintzaras E, Kaditis AG (2014) Omalizumab therapy for allergic bronchopulmonary aspergillosis in children with cystic fibrosis: a synthesis of published evidence. Pediatr Pulmonol 49(5):503–7

    Article  PubMed  Google Scholar 

  26. van der Ent CK, Hoekstra H, Rijkers GT (2007) Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 62(3):276–7

    Article  PubMed Central  PubMed  Google Scholar 

  27. Lehmann S, Pfannenstiel C, Friedrichs F, Kroger K, Wagner N, Tenbrock K (2014) Omalizumab: a new treatment option for allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Ther Adv Respir Dis 8(5):141–9

    Article  CAS  PubMed  Google Scholar 

  28. Jat KR, Walia DK, Khairwa A (2013) Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. Cochrane Database Syst Rev 9:CD010288

    PubMed  Google Scholar 

  29. Tillie-Leblond I, Germaud P, Leroyer C, Tetu L, Girard F, Devouassoux G et al (2011) Allergic bronchopulmonary aspergillosis and omalizumab. Allergy 66(9):1254–6

    Article  CAS  PubMed  Google Scholar 

  30. Perez-de-Llano LA, Vennera MC, Parra A, Guallar J, Marin M, Asensio O et al (2011) Effects of omalizumab in aspergillus-associated airway disease. Thorax 66(6):539–40

    Article  CAS  PubMed  Google Scholar 

  31. Sastre I, Blanco J, Mata H, Garcia F (2012) A case of allergic bronchopulmonary aspergillosis treated with omalizumab. J Investig Allergol Clin Immunol 22(2):145–7

    CAS  PubMed  Google Scholar 

  32. Collins J, Devos G, Hudes G, Rosenstreich D (2012) Allergic bronchopulmonary aspergillosis treated successfully for one year with omalizumab. J Asthma and Allergy 5:65–70

    Article  CAS  Google Scholar 

  33. Homma T, Kurokawa M, Matsukura S, Yamaguchi M, Adachi M. (2013) Anti-IgE therapy for allergic bronchopulmonary aspergillosis. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi

  34. Gonzalez de Olano D, Gonzalez-Mancebo E, Gandolfo Cano M, Melendez Baltanas A, Valeri-Busto V, Maracionero MA et al (2009) Successful treatment of allergic bronchopulmonary candidiasis with a recombinant anti-immunoglobulin E antibody. J Investig Allergol Clin Immunol 19(5):416–7

    CAS  PubMed  Google Scholar 

  35. Wolf BL, Johnson A (2014) Unexpected decrease in total IgE in a patient with allergic bronchopulmonary aspergillosis treated with omalizumab. J Allergy Clin Immunol Prac 2(1):111–3

    Article  Google Scholar 

  36. El-Qutob LD (2012) New methods of prevention and treatment of allergic diseases. Recent Patents Inflamm Allergy Drug Discov 6(1):46–64

    Article  Google Scholar 

  37. Ridolo E, Montagni M, Melli V, Braido F, Incorvaia C, Canonica GW (2014) Pharmacotherapy of allergic rhinitis: current options and future perspectives. Expert Opin Pharmacother 15(1):73–83

    Article  CAS  PubMed  Google Scholar 

  38. Vashisht P, Casale T (2013) Omalizumab for treatment of allergic rhinitis. Expert Opin Biol Ther 13(6):933–45

    Article  CAS  PubMed  Google Scholar 

  39. Lenk C, Duttge G (2014) Ethical and legal framework and regulation for off-label use: European perspective. Ther Clin Risk Manag 10:537–46

    Article  PubMed Central  PubMed  Google Scholar 

  40. Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A et al (2002) Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 109(2):274–80

    Article  CAS  PubMed  Google Scholar 

  41. Kopp MV, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C et al (2009) Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 39(2):271–9

    Article  CAS  PubMed  Google Scholar 

  42. Okubo K, Nagakura T (2008) Anti-IgE antibody therapy for Japanese cedar pollinosis: omalizumab update. Allergol Int 57(3):205–9

    Article  CAS  PubMed  Google Scholar 

  43. Ogino S, Nagakura T, Okubo K, Sato N, Takahashi M, Ishikawa T (2009) Re-treatment with omalizumab at one year interval for Japanese cedar pollen-induced seasonal allergic rhinitis is effective and well tolerated. Int Arch Allergy Immunol 149(3):239–45

    Article  CAS  PubMed  Google Scholar 

  44. Penn R, Mikula S (2007) The role of anti-IgE immunoglobulin therapy in nasal polyposis: a pilot study. Am J Rhinol 21(4):428–32

    Article  PubMed  Google Scholar 

  45. Guglielmo M, Gulotta C, Mancini F, Sacchi M, Tarantini F (2009) Recalcitrant nasal polyposis: achievement of total remission following treatment with omalizumab. J Investig Allergol Clin Immunol 19(2):158–9

    CAS  PubMed  Google Scholar 

  46. Grundmann SA, Hemfort PB, Luger TA, Brehler R (2008) Anti-IgE (omalizumab): a new therapeutic approach for chronic rhinosinusitis. J Allergy Clin Immunol 121(1):257–8

    Article  CAS  PubMed  Google Scholar 

  47. Vennera Mdel C, Picado C, Mullol J, Alobid I, Bernal-Sprekelsen M (2011) Efficacy of omalizumab in the treatment of nasal polyps. Thorax 66(9):824–5

    Article  PubMed  Google Scholar 

  48. Tajiri T, Matsumoto H, Hiraumi H, Ikeda H, Morita K, Izuhara K et al (2013) Efficacy of omalizumab in eosinophilic chronic rhinosinusitis patients with asthma. Ann Allergy Asthma Immunol 110(5):387–8

    Article  CAS  PubMed  Google Scholar 

  49. Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W et al (2013) Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 131(1):110–6

    Article  CAS  PubMed  Google Scholar 

  50. Pinto JM, Mehta N, DiTineo M, Wang J, Baroody FM, Naclerio RM (2010) A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinology 48(3):318–24

    CAS  PubMed  Google Scholar 

  51. Masi AT, Hunder GG, Lie JT, Michel BA, Bloch DA, Arend WP et al (1990) The American college of rheumatology 1990 criteria for the classification of churg-strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33(8):1094–100

    Article  CAS  PubMed  Google Scholar 

  52. Ruppert AM, Averous G, Stanciu D, Deroide N, Riehm S, Poindron V et al (2008) Development of churg-strauss syndrome with controlled asthma during omalizumab treatment. J Allergy Clin Immunol 121(1):253–4

    Article  CAS  PubMed  Google Scholar 

  53. Churg A, Brallas M, Cronin SR, Churg J (1995) Formes frustes of churg-strauss syndrome. Chest 108(2):320–3

    Article  CAS  PubMed  Google Scholar 

  54. Winchester DE, Jacob A, Murphy T (2006) Omalizumab for asthma. N Engl J Med 355(12):1281–2

    Article  CAS  PubMed  Google Scholar 

  55. Bargagli E, Madioni C, Olivieri C, Penza F, Rottoli P (2008) Churg-strauss vasculitis in a patient treated with omalizumab. J Asthma 45(2):115–6

    Article  CAS  PubMed  Google Scholar 

  56. Wechsler ME, Wong DA, Miller MK, Lawrence-Miyasaki L (2009) Churg-strauss syndrome in patients treated with omalizumab. Chest 136(2):507–18

    Article  PubMed  Google Scholar 

  57. Graziani A, Quercia O, Girelli F, Martelli A, Mirici Cappa F, Stefanini GF (2014) Omalizumab treatment in patient with severe asthma and eosinophilic granulomatosis with polyangiitis a case report. Eur Ann Allergy Clin Immunol 46(6):226–8

    CAS  PubMed  Google Scholar 

  58. Pabst S, Tiyerili V, Grohe C (2008) Apparent response to anti-IgE therapy in two patients with refractory “forme fruste” of Churg-Strauss syndrome. Thorax 63(8):747–8

    Article  CAS  PubMed  Google Scholar 

  59. Iglesias E, Camacho Lovillo M, Delgado Pecellin I, Lirola Cruz MJ, Falcon Neyra MD, Salazar Quero JC et al (2014) Successful management of churg-strauss syndrome using omalizumab as adjuvant immunomodulatory therapy: first documented pediatric case. Pediatr Pulmonol 49(3):E78–81

    Article  CAS  PubMed  Google Scholar 

  60. Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J (2007) Administration of anti-IgE to a churg-strauss syndrome patient. Int Arch Allergy Immunol 144(2):155–8

    Article  PubMed  Google Scholar 

  61. Spina MF, Miadonna A (2009) Role of omalizumab and steroids in churg-strauss syndrome. J Allergy Clin Immunol 124(3):600–1

    Article  PubMed  Google Scholar 

  62. Kaya H, Gumus S, Ucar E, Aydogan M, Musabak U, Tozkoparan E et al (2012) Omalizumab as a steroid-sparing agent in chronic eosinophilic pneumonia. Chest 142(2):513–6

    Article  CAS  PubMed  Google Scholar 

  63. Domingo C, Pomares X (2013) Can omalizumab be effective in chronic eosinophilic pneumonia? Chest 143(1):274

    Article  PubMed  Google Scholar 

  64. Barnig C, Hilger C, Muti D, Blaumeiser M, Purohit A, Hentges F et al (2012) Anaphylaxis to vapors of roasting chicken controlled by omalizumab. J Investig Allergol Clin Immunol 22(6):439–40

    CAS  PubMed  Google Scholar 

  65. Perez Pimiento A, Bueso Fernandez A, Garcia Loria J, Rodriguez Cabreros MI, Mosquera MR, Garcia CA (2008) Effect of omalizumab treatment in a baker with occupational asthma. J Investig Allergol Clin Immunol 18(6):490–1

    CAS  PubMed  Google Scholar 

  66. Olivieri M, Biscardo CA, Turri S, Perbellini L (2008) Omalizumab in persistent severe bakers’ asthma. Allergy 63(6):790–1

    Article  CAS  PubMed  Google Scholar 

  67. Lavaud F, Bonniaud P, Dalphin JC, Leroyer C, Muller D, Tannous R et al (2013) Usefulness of omalizumab in ten patients with severe occupational asthma. Allergy 68(6):813–5

    Article  CAS  PubMed  Google Scholar 

  68. Brown R, Turk F, Dale P, Bousquet J (2007) Cost-effectiveness of omalizumab in patients with severe persistent allergic asthma. Allergy 62(2):149–53

    Article  CAS  PubMed  Google Scholar 

  69. Ozturk AB, Kocaturk E (2014) Omalizumab in recurring larynx angioedema: a case report. Asia Pacific Allergy 4(2):129–30

    Article  PubMed Central  PubMed  Google Scholar 

  70. Baker R. (1998) FDA proposes new rules for off-label use of prescription drugs. Food and Drug Administration. BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation. 8–9

  71. O’Reilly J, Dalal A (2003) Off-label or out of bounds? prescriber and marketer liability for unapproved uses of FDA-approved drugs. Annals Health Law / Loyola Univ Chicago, School Law Ins Health Law 12(2):295–324, table of contents

    Google Scholar 

  72. Turner S, Gill A, Nunn T, Hewitt B, Choonara I (1996) Use of “off-label” and unlicensed drugs in paediatric intensive care unit. Lancet 347(9000):549–50

    Article  CAS  PubMed  Google Scholar 

  73. Krathen RA, Hsu S (2005) Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 53(2):338–40

    Article  PubMed  Google Scholar 

  74. Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ (2006) Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 54(1):68–72

    Article  PubMed  Google Scholar 

  75. Vigo PG, Girgis KR, Pfuetze BL, Critchlow ME, Fisher J, Hussain I (2006) Efficacy of anti-IgE therapy in patients with atopic dermatitis. J Am Acad Dermatol 55(1):168–70

    Article  PubMed  Google Scholar 

  76. Belloni B, Ziai M, Lim A, Lemercier B, Sbornik M, Weidinger S et al (2007) Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 120(5):1223–5

    Article  CAS  PubMed  Google Scholar 

  77. Forman SB, Garrett AB (2007) Success of omalizumab as monotherapy in adult atopic dermatitis: case report and discussion of the high-affinity immunoglobulin E receptor. FcepsilonRI Cutis 80(1):38–40

    PubMed  Google Scholar 

  78. Incorvaia C, Pravettoni C, Mauro M, Yacoub MR, Tarantini F, Riario-Sforza GG (2008) Effectiveness of omalizumab in a patient with severe asthma and atopic dermatitis. Monaldi Arch Chest Dis 69(2):78–80

    CAS  PubMed  Google Scholar 

  79. Sheinkopf LE, Rafi AW, Do LT, Katz RM, Klaustermeyer WB (2008) Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc 29(5):530–7

    Article  CAS  PubMed  Google Scholar 

  80. Caruso C, Gaeta F, Valluzzi RL, Romano A (2010) Omalizumab efficacy in a girl with atopic eczema. Allergy 65(2):278–9

    Article  CAS  PubMed  Google Scholar 

  81. Park SY, Choi MR, Na JI, Youn SW, Park KC, Huh CH (2010) Recalcitrant atopic dermatitis treated with omalizumab. Ann Dermatol 22(3):349–52

    Article  PubMed Central  PubMed  Google Scholar 

  82. Thaiwat S, Sangasapaviliya A (2011) Omalizumab treatment in severe adult atopic dermatitis. Asian Pac J Allergy Immunol 29(4):357–60

    CAS  PubMed  Google Scholar 

  83. Ramirez del Pozo ME, Contreras Contreras E, Lopez Tiro J, Gomez VJ (2011) Omalizumab (an anti-IgE antibody) in the treatment of severe atopic eczema. J Investig Allergol Clin Immunol 21(5):416–7

    CAS  PubMed  Google Scholar 

  84. Fernandez-Anton Martinez MC, Leis-Dosil V, Alfageme-Roldan F, Paravisini A, Sanchez-Ramon S, Suarez FR (2012) Omalizumab for the treatment of atopic dermatitis. Actas Dermo-sifilio Graficas 103(7):624–8

    Article  CAS  Google Scholar 

  85. Sanchez-Ramon S, Eguiluz-Gracia I, Rodriguez-Mazariego ME, Paravisini A, Zubeldia-Ortuno JM, Gil-Herrera J et al (2013) Sequential combined therapy with omalizumab and rituximab: a new approach to severe atopic dermatitis. J Investig Allergol Clin Immunol 23(3):190–6

    CAS  PubMed  Google Scholar 

  86. Kim DH, Park KY, Kim BJ, Kim MN, Mun SK (2013) Anti-immunoglobulin E in the treatment of refractory atopic dermatitis. Clin Exp Dermatol 38(5):496–500

    Article  CAS  PubMed  Google Scholar 

  87. Iyengar SR, Hoyte EG, Loza A, Bonaccorso S, Chiang D, Umetsu DT et al (2013) Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial. Int Arch Allergy Immunol 162(1):89–93

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  88. Toledo F, Silvestre JF, Munoz C (2012) Combined therapy with low-dose omalizumab and intravenous immunoglobulin for severe atopic dermatitis report of four cases. J Eur Acad Dermatol Venereol 26(10):1325–7

    Article  CAS  PubMed  Google Scholar 

  89. Hotze M, Baurecht H, Rodriguez E, Chapman-Rothe N, Ollert M, Folster-Holst R et al (2014) Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines. Allergy 69(1):132–5

    Article  CAS  PubMed  Google Scholar 

  90. Fairman KA, Curtiss FR (2010) Regulatory actions on the off-label use of prescription drugs: ongoing controversy and contradiction in 2009 and 2010. J Manag Care Pharm JMCP 16(8):629–39

    PubMed  Google Scholar 

  91. Messingham KA, Holahan HM, Fairley JA (2014) Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid. Immunol Res 59(1–3):273–8

    Article  CAS  PubMed  Google Scholar 

  92. Fairley JA, Baum CL, Brandt DS, Messingham KA (2009) Pathogenicity of IgE in autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol 123(3):704–5

    Article  PubMed  Google Scholar 

  93. London VA, Kim GH, Fairley JA, Woodley DT (2012) Successful treatment of bullous pemphigoid with omalizumab. Arch Dermatol 148(11):1241–3

    Article  PubMed  Google Scholar 

  94. Dufour C, Souillet AL, Chaneliere C, Jouen F, Bodemer C, Jullien D et al (2012) Successful management of severe infant bullous pemphigoid with omalizumab. Br J Dermatol 166(5):1140–2

    Article  CAS  PubMed  Google Scholar 

  95. Yu KK, Crew AB, Messingham KA, Fairley JA, Woodley DT (2014) Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol 71(3):468–74

    Article  CAS  PubMed  Google Scholar 

  96. Yalcin AD, Genc GE, Celik B, Gumuslu S (2014) Anti-IgE monoclonal antibody (omalizumab) is effective in treating bullous pemphigoid and its effects on soluble CD200. Clin Lab 60(3):523–4

    PubMed  Google Scholar 

  97. Nonaka M, Sakitani E, Yoshihara T (2014) Anti-IgE therapy to Kimura’s disease: a pilot study. Auris Nasus Larynx 41(4):384–8

    Article  PubMed  Google Scholar 

  98. Centers for medicare & medicaid services: off-label use of colorectal cancer drugs allowed in select clinical trials. Journal of oncology practice / American Society of Clinical Oncology. (2005)1(1):12–4

  99. Chularojanamontri L, Wimoolchart S, Tuchinda P, Kulthanan K, Kiewjoy N (2009) Role of omalizumab in a patient with hyper-IgE syndrome and review dermatologic manifestations. Asian Pac J Allergy Immunol 27(4):233–6

    PubMed  Google Scholar 

  100. Rodriguez-Rodriguez M, Antolin-Amerigo D, Barbarroja-Escudero J, Sanchez-Gonzalez MJ, Alvarez-Mon M (2014) Successful treatment of severe delayed pressure angio-oedema with omalizumab. Allergol Immun (Madr) 42(1):78–80

    Article  CAS  Google Scholar 

  101. Bindslev-Jensen C, Skov PS (2010) Efficacy of omalizumab in delayed pressure urticaria: a case report. Allergy 65(1):138–9

    Article  CAS  PubMed  Google Scholar 

  102. Ozturk AB, Kocaturk E, Ozturk E (2014) Successful treatment of a bullous urticaria with omalizumab. Allergol Int 63(3):495–7

    Article  PubMed  Google Scholar 

  103. Pressler A, Grosber M, Halle M, Ring J, Brockow K (2013) Failure of omalizumab and successful control with ketotifen in a patient with vibratory angio-oedema. Clin Exp Dermatol 38(2):151–3

    Article  CAS  PubMed  Google Scholar 

  104. Mur Gimeno P, Martin Iglesias A, Lombardero Vega M, Bautista Martinez P, Ventura LP (2013) Occupational wheat contact dermatitis and treatment with omalizumab. J Investig Allergol Clin Immunol 23(4):287–8

    CAS  PubMed  Google Scholar 

  105. Carballada F, Nunez R, Martin-Lazaro J, Juarez Y, Castineira I, Fernandez L et al (2013) Omalizumab treatment in 2 cases of refractory heat urticaria. J Investig Allergol Clin Immunol 23(7):519–21

    CAS  PubMed  Google Scholar 

  106. Bullerkotte U, Wieczorek D, Kapp A, Wedi B (2010) Effective treatment of refractory severe heat urticaria with omalizumab. Allergy 65(7):931–2

    Article  CAS  PubMed  Google Scholar 

  107. Duchini G, Baumler W, Bircher AJ, Scherer K (2011) Failure of omalizumab (Xolair(R)) in the treatment of a case of solar urticaria caused by ultraviolet A and visible light. Photodermatol Photoimmunol Photomed 27(6):336–7

    Article  CAS  PubMed  Google Scholar 

  108. Guzelbey O, Ardelean E, Magerl M, Zuberbier T, Maurer M, Metz M (2008) Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy 63(11):1563–5

    Article  CAS  PubMed  Google Scholar 

  109. Sands MF, Blume JW, Schwartz SA (2007) Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab. J Allergy Clin Immunol 120(4):979–81

    Article  CAS  PubMed  Google Scholar 

  110. Larenas-Linnemann D, Wahn U, Kopp M (2014) Use of omalizumab to improve desensitization safety in allergen immunotherapy. J Allergy Clin Immunol 133(3):937–e2

    Article  CAS  PubMed  Google Scholar 

  111. Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG et al (2006) Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 117(1):134–40

    Article  CAS  PubMed  Google Scholar 

  112. Stelmach I, Sztafinska A, Woicka-Kolejwa K, Jerzynska J (2014) Omalizumab in the prevention of anaphylaxis during immunotherapy: a case report. Postepy dermatologii i alergologii 31(3):191–3

    PubMed Central  PubMed  Google Scholar 

  113. Massanari M, Nelson H, Casale T, Busse W, Kianifard F, Geba GP et al (2010) Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 125(2):383–9

    Article  CAS  PubMed  Google Scholar 

  114. Tartibi HM, Majmundar AR, Khan DA (2010) Successful use of omalizumab for prevention of fire ant anaphylaxis. J Allergy Clin Immunol 126(3):664–5

    Article  PubMed  Google Scholar 

  115. Tille KS, Parker AL (2014) Imported fire ant rush desensitization using omalizumab and a premedication regimen. Ann Allergy Asthma Immunol 113(5):574–6

    Article  PubMed  Google Scholar 

  116. Wieczorek D, Kapp A, Wedi B (2014) Intolerance of specific immunotherapy with Hymenoptera venom: jumping the hurdle with omalizumab. Hautarzt 65(9):791–5, Unvertraglichkeit der spezifischen Immuntherapie mit Hymenopterengift: Mit Omalizumab die Hurde nehmen

    Article  CAS  PubMed  Google Scholar 

  117. Leung DY, Sampson HA, Yunginger JW, Burks AW Jr, Schneider LC, Wortel CH et al (2003) Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 348(11):986–93

    Article  CAS  PubMed  Google Scholar 

  118. Sampson HA, Leung DY, Burks AW, Lack G, Bahna SL, Jones SM et al (2011) A phase II, randomized, doubleblind, parallelgroup, placebocontrolled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 127(5):1309–10

    Article  CAS  PubMed  Google Scholar 

  119. Schneider LC, Rachid R, LeBovidge J, Blood E, Mittal M, Umetsu DT (2013) A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients. J Allergy Clin Immunol 132(6):1368–74

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  120. Savage JH, Courneya JP, Sterba PM, Macglashan DW, Saini SS, Wood RA (2012) Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. J Allergy Clin Immunol 130(5):1123–9

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  121. Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT (2011) Rapid oral desensitization in combination with omalizumab therapy in patients with cow’s milk allergy. J Allergy Clin Immunol 127(6):1622–4

    Article  PubMed Central  PubMed  Google Scholar 

  122. Begin P, Dominguez T, Wilson SP, Bacal L, Mehrotra A, Kausch B et al (2014) Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab. Allergy Asthma Clin Immunol 10(1):7

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  123. Lafuente I, Mazon A, Nieto M, Uixera S, Pina R, Nieto A. (2014) Possible recurrence of symptoms after discontinuation of omalizumab in anti-IgE-assisted desensitization to egg. Pediatr Allergy Immunol

  124. Manohar M, Nadeau KC (2014) The potential of anti-IgE in food allergy therapy. Curr Treat Options Allergy 1(2):145–56

    Article  PubMed Central  PubMed  Google Scholar 

  125. Rocha R, Vitor AB, Trindade E, Lima R, Tavares M, Lopes J et al (2011) Omalizumab in the treatment of eosinophilic esophagitis and food allergy. Eur J Pediatr 170(11):1471–4

    Article  CAS  PubMed  Google Scholar 

  126. Robyn J, Metcalfe DD (2006) Systemic mastocytosis. Adv Immunol 89:169–243

    Article  CAS  PubMed  Google Scholar 

  127. Kontou-Fili K (2008) High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 63(3):376–8

    Article  CAS  PubMed  Google Scholar 

  128. Sokol KC, Ghazi A, Kelly BC, Grant JA (2014) Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report. J Allergy Clin Immunol Prac 2(3):266–70

    Article  Google Scholar 

  129. da Silva EN, Randall KL (2013) Omalizumab mitigates anaphylaxis during ultrarush honey bee venom immunotherapy in monoclonal mast cell activation syndrome. J Allergy Clin Immunol Prac 1(6):687–8

    Article  Google Scholar 

  130. Douglass JA, Carroll K, Voskamp A, Bourke P, Wei A, O’Hehir RE (2010) Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient. Allergy 65(7):926–7

    Article  CAS  PubMed  Google Scholar 

  131. Jagdis A, Vadas P (2014) Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome. Ann Allergy Asthma Immunol 113(1):115–6

    Article  PubMed  Google Scholar 

  132. Paraskevopoulos G, Sifnaios E, Christodoulopoulos K, Mantopoulou F, Papakonstantis M, Sabaziotis D (2013) Successful treatment of mastocytic anaphylactic episodes with reduction of skin mast cells after anti-IgE therapy. Eur Ann Allergy Clin Immunol 45(2):52–5

    CAS  PubMed  Google Scholar 

  133. Matito A, Blazquez-Goni C, Morgado JM, Alvarez-Twose I, Mollejo M, Sanchez-Munoz L et al (2013) Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis. Ann Allergy Asthma Immunol 111(5):425–6

    Article  PubMed  Google Scholar 

  134. Bell MC, Jackson DJ (2012) Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab. Ann Allergy Asthma Immunol 108(5):383–4

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  135. Kibsgaard L, Skjold T, Deleuran M, Vestergaard C (2014) Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis. Acta Derm Venereol 94(3):363–4

    Article  PubMed  Google Scholar 

  136. Siebenhaar F, Kuhn W, Zuberbier T, Maurer M (2007) Successful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy. J Allergy Clin Immunol 120(1):213–5

    Article  CAS  PubMed  Google Scholar 

  137. Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe DD (2007) Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol 119(6):1550–1

    Article  CAS  PubMed  Google Scholar 

  138. Bray SM, Fajt ML, Petrov AA (2012) Successful treatment of exercise-induced anaphylaxis with omalizumab. Ann Allergy Asthma Immunol 109(4):281–2

    Article  CAS  PubMed  Google Scholar 

  139. Lee J (2014) Successful prevention of recurrent anaphylactic events with anti-immunoglobulin E therapy. Asia Pacific allergy 4(2):126–8

    Article  PubMed Central  PubMed  Google Scholar 

  140. Demirturk M, Gelincik A, Colakoglu B, Dal M, Buyukozturk S (2012) Promising option in the prevention of idiopathic anaphylaxis: omalizumab. J Dermatol 39(6):552–4

    Article  CAS  PubMed  Google Scholar 

  141. Jones JD, Marney SR Jr, Fahrenholz JM (2008) Idiopathic anaphylaxis successfully treated with omalizumab. Ann Allergy Asthma Immunol 101(5):550–1

    Article  PubMed  Google Scholar 

  142. Berges-Gimeno MP, Simon RA, Stevenson DD (2003) Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 111(1):180–6

    Article  CAS  PubMed  Google Scholar 

  143. Bobolea I, Barranco P, Fiandor A, Cabanas R, Quirce S (2010) Omalizumab: a potential new therapeutic approach for aspirin-exacerbated respiratory disease. J Investig Allergol Clin Immunol 20(5):448–9

    CAS  PubMed  Google Scholar 

  144. Aksu K, Kurt E (2013) Aspirin tolerance following omalizumab therapy in a patient with aspirin-exacerbated respiratory disease. Allergol Immunopathol (Madr) 41(3):208–10

    Article  CAS  Google Scholar 

  145. Vogel Z, Towbin M, Daniels MP (1979) Alpha-bungarotoxin-horseradish peroxidase conjugate: preparation, properties and utilization for the histochemical detection of acetylcholine receptors. J Histochem Cytochem 27(4):846–51

    Article  CAS  PubMed  Google Scholar 

  146. Matheu V, Franco A, Perez E, Hernandez M, Barrios Y (2007) Omalizumab for drug allergy. J Allergy Clin Immunol 120(6):1471–2, author reply 2–3

    Article  PubMed  Google Scholar 

  147. Cavelti-Weder C, Muggli B, Keller C, Babians-Brunner A, Biason-Lauber A, Donath MY et al (2012) Successful use of omalizumab in an inadequately controlled type 2 diabetic patient with severe insulin allergy. Diabetes Care 35(6):e41

    Article  PubMed Central  PubMed  Google Scholar 

  148. Yong PF, Malik R, Arif S, Peakman M, Amiel S, Ibrahim MA et al (2009) Rituximab and omalizumab in severe, refractory insulin allergy. N Engl J Med 360(10):1045–7

    Article  CAS  PubMed  Google Scholar 

  149. Ojaimi S, Harnett PR, Fulcher DA (2014) Successful carboplatin desensitization by using omalizumab and paradoxical diminution of total IgE levels. J Allergy Clin Immunol Prac 2(1):105–6

    Article  Google Scholar 

  150. Heinz C, Heiligenhaus A (2014) Vernal keratoconjunctivitis. Klin Monbl Augenheilkd 231(5):505–11, Keratoconjunctivitis vernalis

    Article  CAS  PubMed  Google Scholar 

  151. Vichyanond P, Pacharn P, Pleyer U, Leonardi A (2014) Vernal keratoconjunctivitis: a severe allergic eye disease with remodeling changes. Pediatr Allergy Immunol 25(4):314–22

    Article  PubMed  Google Scholar 

  152. Sanchez J, Omalizumab CR (2012) An option in vernal keratoconjunctivitis? Allergol Immunopathol (Madr) 40(5):319–20

    Article  CAS  Google Scholar 

  153. de Klerk TA, Sharma V, Arkwright PD, Biswas S (2013) Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab. J AAPOS Off Pub Am Assoc Ped Ophthalmol Strabismus Am Assoc Ped Ophthalmol Strabismus 17(3):305–6

    Article  Google Scholar 

  154. Matsutani S, Kobayashi T, Kousaka T (1995) Eosinophilic otitis media. Otolaryngol Head Neck Surg 67(8):712–3

    Google Scholar 

  155. Kawano T, Ishitoya J, Tsukuda M (2007) Sinusitis with eosinophilic otitis media. Practica Oto-Rhino-Laryngologica 100(9):715–24

    Article  Google Scholar 

  156. Okude A, Tagaya E, Kondo M, Nonaka M, Tamaoki J (2012) A case of severe asthma with eosinophilic otitis media successfully treated with anti-IgE monoclonal antibody omalizumab. Case Rep Pulmonol 2012:340525

    PubMed Central  PubMed  Google Scholar 

  157. Iino Y, Hara M, Hasegawa M, Matsuzawa S, Shinnabe A, Kanazawa H et al (2012) Clinical efficacy of anti-IgE therapy for eosinophilic otitis media. Otology Neurotol Off Publ Am Otolog Soc Am Neurotol Soc [and] Eur Acad Otolog Neurotol 33(7):1218–24

    Article  Google Scholar 

  158. Iino Y, Hara M, Hasegawa M, Matsuzawa S, Shinnabe A, Kanazawa H et al (2014) Effect of omalizumab on biomarkers in middle ear effusion in patients with eosinophilic otitis media. Acta Otolaryngol 134(4):366–72

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of Interest

The author declares that there is no conflict of interest.

Author information

Authors and Affiliations

  1. Unit of Allergy, University Hospital of La Plana in Vila-Real, Carretera Vila-Real-Burriana Km. 0.5, Vila-Real, Castellon, 12540, Spain

    David El-Qutob

Authors
  1. David El-Qutob
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David El-Qutob.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

El-Qutob, D. Off-Label Uses of Omalizumab. Clinic Rev Allerg Immunol 50, 84–96 (2016). https://doi.org/10.1007/s12016-015-8490-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12016-015-8490-y

Keywords

Search

Navigation